|| Checking for direct PDF access through Ovid
DFU is one of the most recurrent complication of diabetes, there is not a novel therapy to promote wound healing, including re-epithelization and angiogenesis.Herein, we reported that IDR-1018 induced pro-angiogenin molecules, anti-inflammatory molecules and promoted cell migration.IDR-1018 is a novel an option for therapeutic application with low cost for chronic ulcers.Synthetic innate defence regulator (IDR) peptides such as IDR-1018 modulate immunity to promote key protective functions including chemotaxis, wound healing, and anti-infective activity, while suppressing pro-inflammatory responses to non-pathological levels. Here we demonstrated that IDR-1018 induced, by up to 75-fold, pro-angiogenic VEGF-165 in keratinocytes but suppressed this isoform in endothelial cells. It also induced early angiogenin and prolonged anti-inflammatory TGFβ expression on endothelial cells, while suppressing early pro-inflammatory IL-1β expression levels. IDR-1018 also down-regulated the hypoxia induced transcription factor HIF-1α in both keratinocytes and endothelial cells. Consistent with these data, in an in vitro wound healing scratch assay, IDR-1018 induced migration of endothelial cells under conditions of hypoxia while in epithelial cells migration increased only under conditions of normoxia.